Current label answer
Wegovy labeling connects digestive fluid loss with kidney injury risk
The manufacturer Wegovy label effective June 18, 2026 covers subcutaneous injection and once-daily tablets. Its acute-kidney-injury warning says most postmarketing events occurred in people who experienced gastrointestinal adverse reactions leading to dehydration, including nausea, vomiting, or diarrhea. It directs clinicians to monitor kidney function when adverse reactions could lead to volume depletion, especially during treatment initiation and escalation. This establishes a recognized safety pathway; it does not mean every digestive symptom has caused dehydration or kidney injury.
- Nausea, vomiting, and diarrhea can reduce intake or increase losses, but the clinical effect depends on severity, duration, actual intake, medical history, other medicines, and the individual pattern.
- The label does not publish a single percentage for “Wegovy dehydration” that predicts one patient’s risk.
- Do not use thirst, urine color, scale changes, or a wearable reading alone to diagnose dehydration or kidney injury.
Symptoms and context
Assess fluid losses, intake, urination, and function together
MedlinePlus lists thirst, dry mouth, urinating less than usual, dark urine, tiredness, and dizziness among dehydration symptoms in adults. Those findings are not specific to Wegovy and may overlap with low blood sugar, low blood pressure, infection, heat illness, kidney problems, another medicine, or another condition. A useful message to the care team explains which symptoms are occurring together and whether food and fluids stay down.
- Record vomiting and diarrhea frequency, fluid and food intake, urine frequency and color, dizziness when standing, weakness, confusion, fainting, fever, and recent heat exposure or illness.
- Include constipation, abdominal swelling, severe or persistent pain, and whether stool or gas can pass because abdominal warning signs may require a different urgent evaluation.
- Avoid a homemade salt, sugar, potassium, or electrolyte recipe; fluid guidance can differ with kidney or heart disease, pregnancy, blood-pressure treatment, or a prescribed fluid restriction.
Injection and tablet distinctions
Route-specific side-effect data should not be pooled into one personal forecast
The current Wegovy label includes weekly injection and daily tablet presentations, but their study tables and administration routines are formulation-specific. In pooled adult weight-reduction trials of the 2.4 mg weekly injection, nausea occurred in 44% of Wegovy participants versus 16% receiving placebo, diarrhea in 30% versus 16%, and vomiting in 24% versus 6%. Those rates help explain why hydration questions matter, but they are not dehydration rates and should not be transferred to tablets, adolescents, Ozempic, another dose or indication, or compounded semaglutide.
- Confirm whether the patient has a Wegovy pen, prefilled syringe, FlexTouch pen, tablet package, another branded semaglutide product, or a compounded prescription.
- Keep an injection percentage tied to its labeled population, route, dose, and study rather than presenting it as a universal Wegovy risk.
- Do not assume tablets are milder, injections are stronger, or more symptoms prove better absorption or greater weight loss.
Kidneys, glucose, and other medicines
Medical history and medication overlap can change the response
Kidney disease, heart disease, older age, fever, a prescribed fluid restriction, and medicines that affect fluid balance, blood pressure, glucose, or kidney function can make generic hydration advice inappropriate. Wegovy can also increase low-blood-sugar risk when used with insulin or an insulin secretagogue such as a sulfonylurea. Dizziness, weakness, sweating, confusion, or faintness therefore needs the person’s glucose plan and complete medication context—not an assumption that dehydration is the only explanation.
- Share kidney and heart history, blood-pressure trends, glucose readings when monitoring is part of care, insulin, sulfonylureas, diuretics, ACE inhibitors, ARBs, SGLT2 inhibitors, NSAIDs, laxatives, and recent illnesses.
- Ask whether kidney function, electrolytes, glucose, blood pressure, or an in-person examination should be checked based on the actual symptom pattern.
- Do not independently stop diabetes or blood-pressure medicines, skip or repeat Wegovy, or create a self-directed hold, restart, or catch-up plan.
Product and pharmacy identity
Wegovy, Ozempic, and compounded semaglutide are not interchangeable labels
Wegovy and Ozempic contain semaglutide but have distinct product labels, indications, presentations, study populations, and instructions. A patient-specific compounded semaglutide preparation is not FDA-approved Wegovy, is not an FDA-approved generic Wegovy finished product, and may differ in concentration, inactive ingredients, additives, container, storage, beyond-use date, and pharmacy directions. The exact package or dispensing label should anchor the review before a treatment decision.
- Preserve the product name, route, strength or concentration, presentation, manufacturer or dispensing pharmacy, refill or lot details, storage history, and a photo of the current label.
- A changed container, concentration, pharmacy, additive, storage condition, or unclear unit marking should be reviewed before the next treatment decision.
- Avoid no-prescription checkout, research-use products marketed for people, counterfeit tablets or pens, unlabeled vials, and “generic Wegovy” claims.
Escalation and follow-up
Persistent symptoms and emergency warning signs need different pathways
For a non-emergency pattern, the prescriber can review the exact product, fluid losses, intake, urination, glucose or blood-pressure context, other medicines, and medical history before deciding whether monitoring, testing, supportive care, or a treatment change is appropriate. Severe dehydration can become dangerous, while severe abdominal pain or repeated vomiting can also signal a problem that should not be managed as hydration alone. Urgent symptoms should not wait for a routine portal response or the next refill visit.
- Contact the prescriber for persistent or worsening nausea, vomiting, diarrhea, poor intake, dark urine, reduced urination, dizziness, weakness, symptoms during initiation or escalation, or uncertainty before the next treatment decision.
- Seek prompt in-person care for repeated vomiting, inability to keep fluids down, fainting, confusion, lack of urination, severe weakness, severe or persistent abdominal pain, blood or black stool, jaundice, or rapid worsening.
- Trouble breathing, facial or throat swelling, collapse, or widespread hives with breathing difficulty requires emergency evaluation.